Journal of Dermatology最新文献

{"title":"Efficacy of granulocyte and monocyte adsorptive apheresis on skin and joint manifestations of palmoplantar pustulosis with pustulotic arthro-osteitis: A multicentric, prospective, observational study","authors":"Namiko Abe,&nbsp;Yuko Higashi,&nbsp;Chiharu Tateishi,&nbsp;Takuro Kanekura,&nbsp;Daisuke Tsuruta,&nbsp;Tomoko Kobayashi,&nbsp;Yukari Okubo","doi":"10.1111/1346-8138.17667","DOIUrl":"10.1111/1346-8138.17667","url":null,"abstract":"<p>Granulocyte and monocyte adsorptive apheresis (GMA) selectively removes activated granulocytes and monocytes from the peripheral blood. In 2012, GMA was approved in Japan as a treatment for generalized pustular psoriasis and localized pustular psoriasis or palmoplantar pustulosis (PPP). Limited evidence from case reports and monocentric studies suggested that GMA is an effective treatment for skin and joint symptoms of PPP with pustulotic arthro-osteitis (PAO). The present, prospective, observational study was performed at three dermatology departments in Japan to evaluate the efficacy and safety of GMA in patients with PPP with PAO. Between April 2017 and December 2020, two male and 12 female patients with PPP and PAO were enrolled. Their mean age, mean duration of skin manifestations, and mean duration of PAO symptoms was 52.8 years, 51.2 months, and 44.9 months, respectively. GMA was applied weekly over five sessions. The skin and joint symptoms were assessed at baseline, post-GMA, and at the 3-month follow-up. A total of 12 patients completed five GMA sessions, and two patients discontinued the treatment because of adverse events. Thus, 12 patients were finally assessed post-GMA, and 10 patients were assessed at the 3-month follow-up. The assessment of GMA efficacy demonstrated that the skin symptoms had remarkably improved and improved in 33.3% (4/12) and 70% (7/10) of the patients post-GMA and at the 3-month follow-up, respectively. Furthermore, the joint symptoms had remarkably improved in 66.7% (8/12) and 60% (6/10) of the patients post-GMA and at the 3-month follow-up, respectively. These results suggest that GMA is effective in treating the skin and joint symptoms of PPP with PAO.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"642-650"},"PeriodicalIF":2.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17667","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and meta-analysis of peripheral blood inflammatory markers in hidradenitis Suppurativa","authors":"Yan-Han Li,&nbsp;Shu-Han Chuang,&nbsp;Hui-Ju Yang","doi":"10.1111/1346-8138.17661","DOIUrl":"10.1111/1346-8138.17661","url":null,"abstract":"<p>Despite the systemic inflammatory implications of hidradenitis suppurativa (HS), the relationship between systemic inflammatory markers and HS has not been definitively established in the existing literature. This review aimed to evaluate the relationship of peripheral blood inflammatory markers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), pan-immune-inflammation value (PIV) and systemic immune-inflammation index (SII) with the presence and severity of HS. A comprehensive search of the PubMed, Embase and Cochrane databases was conducted. Studies with data on these peripheral blood inflammatory markers in HS patients were included. A meta-analysis was performed using standardized mean differences to evaluate the association between these inflammatory markers and HS. Our study included 23 research articles that included 2623 cases and 22 015 controls. The results demonstrated that (1) CRP, ESR, NLR, and SII levels were significantly higher in HS patients than controls, and (2) CRP, ESR, PIV, and SII positively correlated with HS severity between Hurley stages I and II and II and III. NLR and PLR also correlated with severity between stages II and III. CRP, ESR, NLR and SII are significantly associated with the presence of HS, while CRP, ESR, SII, and PIV are important indicators of HS severity. NLR and PLR become particularly significant in groups with severe HS. Our results underscore the systemic inflammatory involvement in HS and suggest that these inflammatory markers could be valuable in clinical practice for screening and monitoring the progression of HS.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"583-592"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of BP180, BP230, and type VII collagen antibody titers in serum, blister fluid, erosion, and saliva in pemphigoid diseases","authors":"Hiroshi Koga,&nbsp;Norito Ishii,&nbsp;Masahiro Tsutsumi,&nbsp;Kwesi Teye,&nbsp;Mieko Kosaka,&nbsp;Takekuni Nakama","doi":"10.1111/1346-8138.17647","DOIUrl":"10.1111/1346-8138.17647","url":null,"abstract":"<p>Autoantibodies, including anti-BP180 and anti-BP230 antibodies in bullous pemphigoid (BP) and mucous membrane pemphigoid (MMP), and anti-type VII collagen (COL7) antibodies in epidermolysis bullosa acquisita (EBA), are well characterized. Enzyme-linked immunosorbent assays (ELISAs) for the detection of these antibodies in the serum are valuable for diagnosis. Previous studies have indicated that anti-BP180 and anti-BP230 antibodies in blister fluid and saliva can be detected using ELISA. The aim of this study was to detect anti-BP180, anti-BP230, and anti-COL7 antibodies in several types of samples, including blister fluid, an erosive surface swab, and saliva, by ELISAs and to compare the titers of these antibodies between different types of samples. Thirty-three patients with BP/MMP, two patients with EBA, and 13 patients with non-pemphigoid diseases were included in this study. Samples were collected from each patient and analyzed using commercial ELISA kits. In the cases of BP/MMP, the mean ± standard deviation indices of BP180 ELISA were 411.9 ± 538.3, 253.5 ± 333.3, 2.360 ± 1.714, and 1.599 ± 1.262, and those of BP230 ELISA were 27.73 ± 37.65, 20.52 ± 30.04, 0.486 ± 0.7915, and 0.346 ± 0.4373, from sera, blister fluids, erosive surface swabs, and saliva, respectively. The indices of BP180 and BP230 ELISAs using serum were significantly correlated with those of BP180 and BP230 ELISAs using blister fluid (<i>r</i> = 0.9342 and <i>r</i> = 0.9882), an erosive surface swab (<i>r</i> = 0.7586 and <i>r</i> = 0.9332), and saliva (<i>r</i> = 0.5731 and <i>r</i> = 0.6147), respectively. This study revealed that autoantibodies were detectable in blister fluids, erosive surfaces, and saliva, and their correlation with serum titers in pemphigoid diseases was highest in blister fluid. In summary, blister fluid can be a minimally invasive sample alternative to serum for the detection of pemphigoid-related antibodies.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"744-748"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanoma","authors":"Ken Horisaki,&nbsp;Shusuke Yoshikawa,&nbsp;Shoichiro Mori,&nbsp;Wataru Omata,&nbsp;Arata Tsutsumida,&nbsp;Yoshio Kiyohara","doi":"10.1111/1346-8138.17613","DOIUrl":"10.1111/1346-8138.17613","url":null,"abstract":"<p>The recent availability of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignant melanoma (MM). However, many patients with MM do not benefit from ICI treatment. As immunotherapy is associated with significant toxicity and high treatment costs despite its excellent efficacy, it is pertinent to select patients who are likely to respond to ICIs. In this single-center, retrospective study we investigated whether the controlling nutritional status (CONUT) score is a useful prognostic marker in Japanese patients with advanced-stage cancer. We analyzed 123 patients with stage IV MM treated with ICIs as first-line systemic treatment at our hospital between February 2012 and July 2024. Receiver operating characteristic curve analysis was used to calculate the CONUT cut-off value and CONUT into two groups of ≥3 and ≤2. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan–Meier method, and differences in survival were assessed using the log-rank test. The Cox proportional hazard regression model was used to evaluate independent prognostic factors. Objective response rate (ORR), PFS, and OS were significantly low in the CONUT ≥3 group, characterized by low nutritional status and high inflammation. Multivariate analysis identified the CONUT score as an independent prognostic factor for both PFS and OS. The CONUT score was not significantly associated with the development of serious immune-related adverse events. The simplicity of the CONUT score may aid in identifying patients with MM who are suitable candidates for ICI treatment.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"615-623"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17613","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score and establishment of novel score in Japanese patients with necrotizing fasciitis (J-LRINEC score)","authors":"Yuta Norimatsu,&nbsp;Takemichi Fukasawa,&nbsp;Yuki Ohno,&nbsp;Yurie Norimatsu,&nbsp;Kazuki M. Matsuda,&nbsp;Teruyoshi Hisamoto,&nbsp;Hirohito Kotani,&nbsp;Ai Kuzumi,&nbsp;Asako Yoshizaki-Ogawa,&nbsp;Takuya Miyagawa,&nbsp;Koji Oba,&nbsp;Shinichi Sato,&nbsp;Ayumi Yoshizaki","doi":"10.1111/1346-8138.17663","DOIUrl":"10.1111/1346-8138.17663","url":null,"abstract":"<p>The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score is widely used to distinguish between necrotizing fasciitis and cellulitis. However, LRINEC scores are not as sensitive or specific as initially reported, possibly due to differences in patient backgrounds in different countries. Here, we examined the validity of LRINEC scores in Japanese patients. We also investigated the possibility of developing a new scoring system. Patients with necrotizing fasciitis (<i>n</i> = 56) and cellulitis (<i>n</i> = 209) were retrospectively evaluated. The data were split into training (<i>n</i> = 199) and validation (<i>n</i> = 66) datasets. A logistic regression analysis was used to calculate the C-statistics of the LRINEC scores. A new equation was formulated using logistic regression analysis with an appropriate variable selection (Laboratory Risk Indicator for Necrotizing Fasciitis for Japanese Patients [J-LRINEC] score). The J-LRINEC score had a C-statistic of 0.9683, sensitivity of 91.4%, and specificity of 84.8%. The LRINEC score had a C-statistic of 0.914 and specificity of 96%; however, its usefulness was limited by its sensitivity of 68.9%. Our results suggest that the LRINEC score is valid for Japanese patients; however, the J-LRINEC score showed higher sensitivity and specificity, suggesting that it may be a useful tool for differentiating cellulitis from necrotizing fasciitis among Japanese patients.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"439-444"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17663","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term real-world effectiveness of deucravacitinib in psoriasis: A 52-week prospective study stratified by prior apremilast or biologic therapy","authors":"Teppei Hagino,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.17665","DOIUrl":"10.1111/1346-8138.17665","url":null,"abstract":"<p>Real-world evidence on the long-term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories of systemic treatments. We evaluated the 52-week effectiveness of deucravacitinib in patients with psoriasis, stratified by a history of apremilast or biologic usage. This prospective, single-center study included 110 patients with moderate-to-severe psoriasis who received daily deucravacitinib (6 mg). Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores during the treatment were analyzed in subgroups stratified by a history of apremilast or biologic usage. Deucravacitinib decreased PASI and DLQI scores for 52 weeks in psoriasis patients, both with and without prior apremilast or biologic usage. The percent reductions from baseline PASI or DLQI at week 52 were similar in apremilast-experienced patients (92% or 77.9%) and apremilast-naive patients (88.3% or 81.6%), respectively. The achievement rates of PASI 100 or absolute PASI ≤1 at week 52 in apremilast-experienced patients (30.8% or 61.5%) were slightly higher than those in apremilast-naive patients (20.5% or 46.2%). The percent reductions from baseline PASI or DLQI at week 52 in biologic-naive patients (91.6 or 82.8%) were slightly higher than those in biologic-experienced patients (57.6% or 63.6%), respectively. The achievement rates of PASI 75, 100 or absolute PASI ≤1 at week 52 in biologic-naive patients (84.4%, 24.4%, or 53.3%) were slightly higher than those in biologic-experienced patients (57.1%, 14.3%, or 28.6%), respectively. Deucravacitinib generated sustained 52-week effectiveness in diverse patient subgroups, supporting its role as a universal treatment for psoriasis.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"634-641"},"PeriodicalIF":2.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17665","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetaminophen as a possible treatment option for pachydermoperiostosis carrying mutated SLCO2A1: Case series","authors":"Tomoya Takegami,&nbsp;Mami I. Mamiya,&nbsp;Satoru Yonekura,&nbsp;Kazue Yoshida,&nbsp;Ryo Tanaka,&nbsp;Kazuhiko Nakabayashi,&nbsp;Hironori Niizeki,&nbsp;Takashi Nomura,&nbsp;Kenji Kabashima","doi":"10.1111/1346-8138.17651","DOIUrl":"10.1111/1346-8138.17651","url":null,"abstract":"<p>Pachydermoperiostosis (PDP) is a genetic disease characterized by digital clubbing, periostosis, and pachydermia. PDP with these three features, along with cutis verticis gyrata (CVG), is categorized as the “complete form,” whereas cases without CVG are categorized as the “incomplete form.” The condition is linked to elevated levels of systemic prostaglandin E2 (PGE2). About half of PDP patients experience arthralgia. The standard treatment for PDP is selective cyclooxygenase (COX)-2 inhibitors, but long-term usage can cause gastrointestinal side effects. Additionally, mutations in the <i>SLCO2A1</i> can lead to chronic enteropathy associated with the <i>SLCO2A1</i> gene (CEAS), making the use of selective COX-2 inhibitors particularly risky for PDP patients with CEAS. This has prompted the search for alternative treatments. In this study, five PDP patients—three with the complete form and two with the incomplete form—were treated with acetaminophen. The PGE-major urinary metabolite (PGE-MUM) was monitored as a biomarker of disease activity, reflecting systemic PGE2 levels. Before treatment, PGE-MUM levels were significantly elevated in patients with complete form and mildly elevated in those with incomplete form. Following acetaminophen, PGE-MUM levels decreased in patients with complete form, and all patients reported improvement in arthralgia without developing gastrointestinal symptoms. In conclusion, acetaminophen shows promise as an alternative treatment for PDP, effectively reducing PGE-MUM levels in certain patients and alleviating arthralgia while avoiding the gastrointestinal side effects associated with long-term COX-2 inhibitor usage.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"749-753"},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infiltration of M2a macrophages is predominant in genital verruciform xanthoma","authors":"Akira Miyazaki,&nbsp;Tomoki Taki,&nbsp;Shoichiro Mori,&nbsp;Motohito Yamada,&nbsp;Masashi Akiyama","doi":"10.1111/1346-8138.17654","DOIUrl":"10.1111/1346-8138.17654","url":null,"abstract":"&lt;p&gt;Verruciform xanthoma (VX) is a rare erythematous benign warty tumor that was first reported by Sachs in 1903 and named by Shafer in 1971.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; It mainly develops in the genital area and the oral mucosa of the elderly. Histopathologically, papillomatous changes in the epidermis and foam cell infiltration in the dermis are seen. To elucidate the etiology of VX, we immunohistochemically investigated the subtypes of infiltrating macrophages. This study was approved by the ethics committees of Nagoya University Hospital and Toyohashi Municipal Hospital (approval numbers: 2022-0422 and 736, respectively) and was carried out under the Declaration of Helsinki.&lt;/p&gt;&lt;p&gt;A 71-year-old Japanese man (case 1) had a 1.5 × 1-cm erythematous pedunculated verrucous nodule on the scrotum (Supporting Information Figure S1a,b). The tumor had enlarged slowly in the previous 10 years. A comorbidity was prostate cancer, which was under observation. Hematoxylin–eosin staining of the resected nodule showed abundant foamy macrophages in the dermis (Supporting Information Figure S1c,d). These stained strongly positive for CD80 (an M1 macrophage marker), CD163 (an M2a/M2c macrophage marker), and DC-SIGN (an M2a macrophage marker) and weakly positive for CD86 (an M1/M2b macrophage marker), but negative for CCR2 (an M2c macrophage marker) (Supporting Information Figure S2a–f). Double-color immunofluorescence staining revealed a large proportion of the DC-SIGN-positive cells to be positive also for CD163 (a macrophage marker) (Supporting Information Figure S3a), suggesting that the DC-SIGN-positive cells were mainly macrophages, particularly M2a macrophages. CD80- and CD163-positive cells existed independently (Supporting Information Figure S3b). The type 2-related molecules IL-4/13 and TSLP were expressed in the epidermis and around the macrophages (Supporting Information Figure S3c–e). Periostin was more strongly expressed in the dermis in the patients than in the healthy control (Supporting Information Figures S3f, S4, and S5). Periostin can promote M2 macrophage skewing in VX lesions. An 89-year-old Japanese man (case 2) had a verrucous papule of 7 mm in diameter on the scrotum. He also had well-controlled psoriasis vulgaris and had been receiving guselkumab therapy (Supporting Information Figures S6–S8). A 73-year-old Japanese man (case 3) had an erythematous pedunculated verrucous nodule of 2 cm in diameter on the scrotum, which enlarged over the course of 10 months (Supporting Information Figures S9–S11). The results of immunohistochemical staining and immunofluorescent double-staining for infiltrating macrophages were similar to those of case 1, although the staining of DC-SIGN was weak in case 3. Unlike in the VX lesions, infiltrating macrophages in the xanthelasma palpebrarum lesion were negative for CD80 and CCR2 (Supporting Information Figures S12 and S13).&lt;/p&gt;&lt;p&gt;Clinical features and cell surface markers of infiltrating macrophages in the prese","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"556-558"},"PeriodicalIF":2.9,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17654","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticosteroids combined with low-dose methotrexate in the treatment of pemphigus vulgaris: A retrospective cohort study","authors":"Yan Chen,&nbsp;Jiaqi Li,&nbsp;Yuchen Tang,&nbsp;Shan Chong,&nbsp;Panpan Shang,&nbsp;Xixue Chen,&nbsp;Xuejun Zhu,&nbsp;Mingyue Wang","doi":"10.1111/1346-8138.17636","DOIUrl":"10.1111/1346-8138.17636","url":null,"abstract":"<p>The treatment of pemphigus vulgaris (PV) often requires long-term systemic corticosteroids. Although new biologicals like rituximab are changing the landscape, traditional immunosuppressants still prevail in many underdeveloped areas. One such medication is methotrexate (MTX), which has been widely used in autoimmune and autoinflammatory diseases, but its role in treating pemphigus remains somewhat unclear and controversial. This study aimed to evaluate the effect and safety profile of using low-dose MTX in PV patients receiving glucocorticoids. PV patients who visited the Department of Dermatology, Peking University First Hospital from January 2010 to December 2021 were retrospectively screened. Based on different treatment regimens, patients were automatically divided into a corticosteroid monotherapy group and a corticosteroid combined with low-dose MTX group (MTX was administered at a dose of no more than15 mg per week, with a minimum duration of 8 weeks). All patients were followed up for 1 year. A total of 142 patients with PV were eligible for the study (100 in the corticosteroid monotherapy group and 42 in the corticosteroid combined with low-dose MTX group). The Kaplan–Meier curve indicated that the corticosteroid combined with low-dose MTX group achieved a 50% reduction in glucocorticoid use faster, with a <i>P</i> value of 0.0132, especially among patients who initially received more than 60 mg of steroids per day. The inclusion of MTX reduced the occurrence of hyperpilidemia. There was not sufficient evidence to determine if the addition of MTX was associated with more bacterial infection cases for certain. The inclusion of low-dose MTX in the corticosteroid treatment regimen for patients with PV, particularly those receiving high doses, can facilitate the reduction of glucocorticoid dosages and lower the incidence of hyperlipidemia, without increasing the risk of other adverse effects.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"695-700"},"PeriodicalIF":2.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of cell adhesion molecule 1 expression in mycosis fungoides: Diagnostic implications and clinical correlations","authors":"Akihiko Yuki,&nbsp;Riichiro Abe","doi":"10.1111/1346-8138.17652","DOIUrl":"10.1111/1346-8138.17652","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"562-564"},"PeriodicalIF":2.9,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}